

Melanoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/MC481A64B718EN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: MC481A64B718EN

Abstracts

The 7 major melanoma markets reached a value of US\$ 3.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 8.9 Billion by 2034, exhibiting a growth rate (CAGR) of 7.93% during 2024-2034.

The melanoma market has been comprehensively analyzed in IMARC's new report titled "Melanoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Melanoma refers to a type of skin cancer that develops in the cells producing melanin, the pigment responsible for providing color to the skin, eyes, and hair. It can manifest in various ways, but most commonly, it appears as a new mole or a change in an existing mole. Several other potential symptoms of the ailment include the development of sores that do not heal; the appearance of new bumps or lumps under the skin; itchiness, tenderness, or pain in the affected area; etc. Melanoma is typically diagnosed through a combination of physical exams, imaging procedures, and biopsies. During a physical exam, a dermatologist or other healthcare provider will closely examine any mole or other marks on the skin to look for potential signs of melanoma. If a suspicious area is identified, various imaging tests, such as an MRI, CT scan, or and PET scan, can be used to determine the extent of the cancer and if it has spread to other areas of the body. A biopsy is generally necessary to confirm a diagnosis of melanoma.

The increasing cases of exposure to ultraviolet radiation from the sun or tanning beds are primarily driving the melanoma market. Additionally, the rising incidence of several associated risk factors, such as having a large number of moles or atypical moles, fair skin that burns easily, weakened immune system, genetic mutations, etc., is also propelling the market growth. Besides this, the emerging popularity of intralesional

therapy on account of its numerous benefits over systemic therapies, including targeted treatment, convenience, a lower risk of developing drug resistance, etc., is acting as another significant growth-inducing factor. Furthermore, the inflating adoption of reflectance confocal microscopy (RCM) for providing high-resolution images of the skin that can help identify the features of melanoma is also bolstering the market growth. Apart from this, the escalating application of Mohs surgery for treating melanoma located on the face, hands, or feet, where preserving healthy tissue and minimizing scarring are especially important, is further creating a positive outlook for the market. Moreover, the ongoing advancements in screening techniques, such as the introduction of dermoscopy and total body photography, which aid in improving the accuracy and efficiency of disease detection, are expected to drive the melanoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the melanoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for melanoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the melanoma market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the melanoma market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the melanoma market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current melanoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the melanoma market performed so far and how will it perform in the coming

years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the melanoma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the melanoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of melanoma across the seven major markets?

What is the number of prevalent cases (2018-2034) of melanoma by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of melanoma by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of melanoma by type across the seven major markets?

How many patients are diagnosed (2018-2034) with melanoma across the seven major markets?

What is the size of the melanoma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of melanoma?

What will be the growth rate of patients across the seven major markets?

Melanoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for melanoma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the melanoma market?

What are the key regulatory events related to the melanoma market?

What is the structure of clinical trial landscape by status related to the melanoma market?

What is the structure of clinical trial landscape by phase related to the melanoma market?

What is the structure of clinical trial landscape by route of administration related to the melanoma market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 MELANOMA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 MELANOMA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 MELANOMA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Epidemiology by Type (2018-2034)
 - 7.2.6 Diagnosed Cases (2018-2034)
 - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Epidemiology by Type (2018-2034)
 - 7.3.6 Diagnosed Cases (2018-2034)
 - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Epidemiology by Type (2018-2034)
 - 7.4.6 Diagnosed Cases (2018-2034)
 - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Epidemiology by Type (2018-2034)
 - 7.5.6 Diagnosed Cases (2018-2034)
 - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Epidemiology by Type (2018-2034)
 - 7.6.6 Diagnosed Cases (2018-2034)

- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)
 - 7.7.4 Epidemiology by Gender (2018-2034)
 - 7.7.5 Epidemiology by Type (2018-2034)
 - 7.7.6 Diagnosed Cases (2018-2034)
 - 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Epidemiology by Type (2018-2034)
 - 7.8.6 Diagnosed Cases (2018-2034)
 - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Epidemiology by Type (2018-2034)
 - 7.9.6 Diagnosed Cases (2018-2034)
 - 7.9.7 Patient Pool/Treated Cases (2018-2034)

8 MELANOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 MELANOMA - UNMET NEEDS

10 MELANOMA - KEY ENDPOINTS OF TREATMENT

11 MELANOMA - MARKETED PRODUCTS

- 11.1 List of Melanoma Marketed Drugs Across the Top 7 Markets

- 11.1.1 Cotellic (Cobimetinib) - Genentech/Exelixis
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
- 11.1.2 Tafinlar (Dabrafenib) - Novartis
 - 11.1.2.1 Drug Overview
 - 11.1.2.2 Mechanism of Action
 - 11.1.2.3 Regulatory Status
 - 11.1.2.4 Clinical Trial Results
 - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Mekinist (Trametinib) - Novartis
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Imlygic (Trametinib) - Novartis
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Yervoy (Ipilimumab) - Bristol Myers Squibb
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 MELANOMA - PIPELINE DRUGS

- 12.1 List of Melanoma Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Tigilanol tiglate - QBiotics
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action

- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 Tebentafusp - Immunocore
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
- 12.1.3 IMM 60 - Portage Biotech
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 ONCOS102 - Targovax Oy
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 TLPLDC - Elios Therapeutics
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. MELANOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. MELANOMA – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 MELANOMA - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Melanoma - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Melanoma - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Melanoma - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Melanoma - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Melanoma - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Melanoma - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Melanoma - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Melanoma - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Melanoma - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Melanoma - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Melanoma - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Melanoma - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

- 15.6.2 Melanoma - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Melanoma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Melanoma - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Melanoma - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Melanoma - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Melanoma - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Melanoma - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Melanoma - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Melanoma - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Melanoma - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Melanoma - Access and Reimbursement Overview

16 MELANOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 MELANOMA MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 MELANOMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Melanoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/MC481A64B718EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MC481A64B718EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

